SMALL CELL LUNG CANCER (SCLC)

This phase 3 study compares a new drug, tarlatamab, with standard treatments in 509 adults whose small cell lung cancer has returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease and have prog…

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine carcinoma of the lung whose cancer has progressed after platinum-based chemotherapy. The main goals are to check safety, find the best dose, and s…

This study tests different doses of tarlatamab in about 252 adults with small cell lung cancer that has worsened after standard chemotherapy. The goal is to see how well the drug shrinks tumors and controls the disease. Participants receive tarlatamab infusions and are monitored …

This study follows 160 adults with lung cancer to see how their muscle mass, strength, and function change during cancer treatment. Researchers want to learn if these factors affect how well patients tolerate treatment, their quality of life, and overall survival. The goal is to …